Bangladesh, Nov. 10 -- Despite a rise in operating expenses and the cost of goods sold, IBN SINA Pharmaceutical Industry has registered 8 per cent year-on-year growth in consolidated profit to Tk 238.74 million in the first quarter of FY27.

Advertisement This profit growth was primarily driven by increased revenue, improved gross profit margin and lower income tax expenses.

IBN SINA reported consolidated revenue of Tk 4 billion in July-September (Q1), up 7.16 per cent from the corresponding period of the previous year.

During the same period, operating expenses rose 9.55 per cent year-on-year, while the cost of goods sold climbed 6 per cent.

Nevertheless, the company's operating profit jumped 6.62 per cent year-on-year in Q1 FY27 due...